Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(2003): Uede K+, Br J Dermatol 149(4), 757 (11 cases)
Basal cell carcinoma
(2005): Fumal I+, Rev Med Liege 60(4), 217
(2002): Centeno JA+, Environ Health Perspect 110, 883 (chronic
exposure)
(2002): Dorfner B+, Hautarzt 53(8), 542
(2001): Guo HR+, Cancer Causes Control 12(10), 909
(1998): Wong SS+, JAmAcadDermatol38(2 Pt 1), 179
Bowen’s disease
(2005): Fumal I+, Rev Med Liege 60(4), 217
(2004): Watson K+, Clin Exp Dermatol 29(1), 46
(2002): Centeno JA+, Environ Health Perspect 110, 883
(2002): Park JY+, JDermatol29(7), 446
(1998): Wong SS+, JAmAcadDermatol38(2 Pt 1), 179
Bullous dermatitis
(1993): Alain G+, Int J Dermatol 32, 899 (passim)
(1992): Breathnach SM+, Adverse Drug Reactions and the Skin
Blackwell, Oxford, 236 (passim)
(1988): Bork K, CutaneousSideEffectsofDrugsWB Saunders,
114
Carcinoma
(2005): Fumal I+, Rev Med Liege 60(4), 217
(2003): Rossman TG, Mutat Res 533(1), 37
(2002): Hall AH, Toxicol Lett 128(1), 69
(2002): Liu J+, Environ Health Perspect 110(2), 119
(2001): Guo HR+, Cancer Causes Control 12(10), 909
(2001): Rahman MM+, J Toxicol Clin Toxicol 39(7), 683
(2001): Yu HS+, JDermatol28(11), 628
(1997): Schwartz RA, Int J Dermatol 36, 241
(1995): Fawell J, Hum Exp Toxicol 14, 464
(1995): Hsueh YM+, Br J Cancer 71, 109
(1993): Urbach F, Recent Results Cancer Res 128, 243
(1992): Wong O+, Int Arch Occup Environ Health 64, 235
(1989): Bickley LK+, NJMed86, 377
(1988): Chen CJ+, Lancet 1, 414
(1988): Durocher LP+, Union Med Can (French) 117, 345
Dermatitis
(2001): Guo X+, MolCellBiochem222(1), 137
(1995): Barbaud A+, Contact Dermatitis 33, 272
(1986): Wahlberg JE+, Derm Beruf Umwelt (German) 34, 10
Dermatofibrosarcoma protuberans
(1986): Shneidman D+, Cancer 58, 1585
Edema (non-pitting)
(2003): Uede K+, Br J Dermatol 149(4), 757 (13 cases)
(2002): Alam MG+, IntJEnvironHealthRes12(3), 235 (chronic
exposure)
Ephelides
(1995): Gritiyarangsan P+, Photodermatol Photoimmunol
Photomed 11, 174
Erythema
(2003): Uede K+, Br J Dermatol 149(4), 757 (5 cases)
Erythema multiforme
(1990): Vassileva S+, Int J Dermatol 29, 381
(1988): Bork K, CutaneousSideEffectsofDrugsWB Saunders,
145
Erythema nodosum
(1988): Bork K, CutaneousSideEffectsofDrugsWB Saunders,
148
Exanthems
(2003): Uede K+, Br J Dermatol 149(4), 757 (8 cases)
(1993): Alain G+, Int J Dermatol 32, 899 (passim)
Exfoliative dermatitis
(1993): Alain G+, Int J Dermatol 32, 899 (passim)
(1992): Breathnach SM+, Adverse Drug Reactions and the Skin
Blackwell, Oxford, 236 (passim)
Fixed eruption
(1988): Bork K, CutaneousSideEffectsofDrugsWB Saunders,
108
Follicular keratosis
ARSENIC 43
Herpes
(2003): Uede K+, Br J Dermatol 149(4), 757 (3 cases)
Hyperhidrosis
(1993): Alain G+, Int J Dermatol 32, 899 (passim)
Hyperkeratosis (palms and soles) (40%)
(2003): Ahsan H+, Toxicol Lett 143(2), 123
(2002): Alam MG+, IntJEnvironHealthRes12(3), 235 (chronic
exposure)
(2002): Centeno JA+, Environ Health Perspect 110 Suppl 5, 883
(chronic exposure)
(2001): Kurokawa M+, Arch Dermatol 137, 102
(1996): Maloney ME, Dermatol Surg 22, 301 (passim)
Hypomelanosis
(2002): Kadono T+, Int J Dermatol 41(12), 841 (chronic
exposure)
Keratoses
(2005): Fumal I+, Rev Med Liege 60(4), 217
(2004): Watson K+, Clin Exp Dermatol 29(1), 46
(2003): Sengupta MK+, J Toxicol Clin Toxicol 41(7), 963
(2002): Alam MG+, IntJEnvironHealthRes12(3), 235 (chronic
exposure)
(2002): Centeno JA+, Environ Health Perspect 110 Suppl 5, 883
(chronic exposure)
(2002): Kadono T+, Int J Dermatol 41(12), 841 (chronic
exposure)
(2002): Liu J+, Environ Health Perspect 110(2), 119
(2002): Park JY+, JDermatol29(7), 446
(2001): Rahman MM+, J Toxicol Clin Toxicol 39(7), 683
(2001): Yu HS+, JDermatol28(11), 628
(1999): Tondel M+, Environmental Health Perspectives 107, 727
(1998): Guha Mazumder DN+, Int J Epidemiol 27, 871
(1993): Alain G+, Int J Dermatol 32, 899 (passim)
(1992): Breathnach SM+, Adverse Drug Reactions and the Skin
Blackwell, Oxford, 236 (passim)
(1988): Bork K, CutaneousSideEffectsofDrugsWB Saunders,
232
Leukomelanosis
(2002): Alam MG+, IntJEnvironHealthRes12(3), 235 (chronic
exposure)
(2001): Kurokawa M+, Arch Dermatol 137, 102
(2001): Rahman MM+, J Toxicol Clin Toxicol 39(7), 683
(1999): Tondel M+, Environmental Health Perspectives 107, 727
(1993): Sass U+, Dermatology 186, 303
Lichen planus (bullous)
Livedo reticularis
Melanoma
(2004): Beane Freeman LE+, Am J Epidemiol 160(7), 679
(1984): Philipp R+, Br Med J Clin Res Ed 288, 237
(1980): Clough P, BMJ 280, 112
(1980): Evans S, BMJ 280, 403
Melanosis
(2003): Sengupta MK+, J Toxicol Clin Toxicol 41(7), 963
(2002): Alam MG+, IntJEnvironHealthRes12(3), 235 (chronic
exposure)
(2002): Kadono T+, Int J Dermatol 41(12), 841 (chronic
exposure)
(2001): Rahman MM+, J Toxicol Clin Toxicol 39(7), 683
(1992): Breathnach SM+, Adverse Drug Reactions and the Skin
Blackwell, Oxford, 236 (passim)
Merkel cell carcinoma
(1999): Huang-Chun L+, JAmAcadDermatol41, 641
(1998): Tsuruta D+, Br J Dermatol 139, 291
(1997): Ohnishi Y+, JDermatol24, 310
(1991): Huang HP+, J Formos Med Assoc 90, 900
Morphea
Palmar–plantar desquamation
(1996): Maloney ME, Dermatol Surg 22, 301 (passim)
(1996): Matsumura Y+, Int J Cancer 65, 778
(1994): McNutt NS+, Arch Dermatol 130, 225